Loading
Preparing stock search
Loading the search box, recent screening context, and the surrounding editorial guidance.
Help keep us running — this site is free to use and we cover the running costs ourselves. We're open to sponsors and advertising to keep it online. Get in touch.
Heads up — we're updating the site with more recent financial data over the coming days. Thanks for being patient with us.
Loading
Loading the search box, recent screening context, and the surrounding editorial guidance.
Company report
Review the methodology status, formula details, and supporting context for RCE.
Methodology
AAOIFI
DJIM
S&P Shariah
Company
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Debt ratio
Formula
Total Interest-Bearing Debt / Market Capitalization (or Avg for AAOIFI/DJIM)
Thresholds
Cash ratio
Formula
(Cash + Interest-Bearing Securities) / Market Capitalization
Thresholds
Analysis
Financial Data
Company Profile
Financial Data
Haram revenue
Formula
Impermissible Revenue / Total Revenue
Thresholds
Financial Data
Company Website
Methodology
Methodology